Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of prophylactic G-CSF with CHOP in elderly patients with non-Hodgkin lymphoma
NL-OMON22855Phase 3Active, not recruiting
- Sponsor
- HOVON
- Start
- Aug 1994
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of filgrastim, cyclophosphamide, doxorubicin, vincristine and prednisone in non-Hodgkin lymphoma (NHL) (2 arms), sponsored by HOVON. Primary endpoint: Complete response rate. Started Aug 1994; status: active, not recruiting.
02
Drugs
filgrastimcyclophosphamidedoxorubicinvincristineprednisone
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NL-OMON22855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON22855.